News
IR News & Topics
- 2024.09.30
- SymBio Reaches Settlement Agreement in Patent Infringement Litigation Related to TREAKISYM
- 2024.09.30
- Analyst Report[Follow-up Report] (Fair Research)
- 2024.09.18
- Key person interview: Updated the Page
- 2024.08.19
- SymBio Initiates Phase 1b Clinical Trial of IV Brincidofovir in Patients with Lymphoma as a First in Human Study for Oncology
- 2024.08.14
- 中間決算説明会スクリプト(2024年12月期)(Japanese only)
- 2024.08.13
- Article on 2024 1H Earnings Call Featured in Nikkei Biotech Online (Japanese only)
Source: Nikkei Biotech ONLINE, 2024.08.07
Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited. - 2024.08.08
- 2024年12月期中間決算説明会の動画を掲載しました。(Japanese only)
- 2024.08.05
- 中間決算説明会資料(2024年12月期)(Japanese only)
- 2024.08.02
- Analyst Report[Flash report] (Shared Research)
- 2024.08.01
- Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
- 2024.07.12
- SymBio Pharmaceuticals Announces Publication of Research Showing Antiviral Drug Brincidofovir Inhibits Infectious Viral Production of Polyomavirus
- 2024.06.24
- Confirmed Antitumor Effects of Brincidofovir in Peripheral T-Cell Lymphoma Suppression of the oncogenic MYC and Induction of Expression of Immunogenic Response Pathways
- 2024.06.11
- SymBio Announces Enrollment of the First Patient of Phase 2a Clinical Trial of Intravenous Brincidofovir for Treatment of Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
- 2024.06.03
- Notice of Appointment of Corporate Officer
- 2024.05.13
- 株主通信「SymBio VISION vol.25」(Japanese only)
- 2024.05.08
- SymBio Announces Initiation of Phase 2a Clinical Trial (ATHENA) of Intravenous Brincidofovir for Treatment of Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
- 2024.05.08
- 四半期報告書-第20期第1四半期(2024/01/01-2024/03/31) (Japanese only)
- 2024.05.07
- Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
- 2024.05.07
- Revision to Earnings Forecast for FY 2024
- 2024.04.19
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
- 2024.04.19
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
- 2024.04.19
- 訂正臨時報告書(Japanese only)
- 2024.04.19
- Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (5th Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
- 2024.04.08
- Onconova Therapeutics and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc.
- 2024.04.03
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (5th Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (5th Allotment)
- 2024.04.03
- Notice Regarding Adjustment of Exercise Price
- 2024.04.03
- コーポレート・ガバナンスに関する報告書 2024/04/03(Japanese only)
- 2024.04.01
- Notice of Personnel Changes at SymBio Pharma USA, Inc.
- 2024.03.29
- 事業計画及び成長可能性に関する事項(Japanese only)
- 2024.03.26
- 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
- 2024.03.26
- 第19期定時株主総会の動画を掲載しました。(Japanese only)
- 2024.03.25
- 臨時報告書(Japanese only)
- 2024.03.25
- Notice of Shareholder Voting Results for the 19th Annual General Meeting of Shareholders
- 2024.03.25
- Notice of Transfer of EU Orphan Designations of Brincidofovir
- 2024.03.22
- Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2024.03.22
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2024.03.22
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2024.03.18
- Research results showing anti-proliferative activity of brincidofovir in B-cell lymphoma to be presented at the AACR Annual Meeting 2024
- 2024.03.18
- Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (4th Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
- 2024.02.29
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (4th Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (4th Allotment)
- 2024.02.29
- Notice Regarding Adjustment of Exercise Price
- 2024.02.26
- Notice of Convocation of the 19th Ordinary General Meeting of Shareholders
- 2024.02.26
- Information on Shareholders' Meeting: Updated the Page
- 2024.02.22
- Notification of Amendment to the Articles of Incorporation
- 2024.02.20
- Article on 2023 Earnings Call Featured in Nikkei Biotech Online (Japanese only)
Source: Nikkei Biotech ONLINE, 2024.02.15
Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited. - 2024.02.16
- 2023年12月期決算説明会の動画を掲載しました。(Japanese only)
- 2024.02.14
- 決算説明会資料(2023年12月期)(Japanese only)
- 2024.02.13
- Preliminary Results of Phase 2a Clinical Trial of Intravenous Brincidofovir (IV BCV) in Immunocompromised Patients with Adenovirus Infection Selected for Oral Presentation at 50th Annual Meeting of the EBMT in Glasgow
- 2024.02.09
- Analyst Report[Full report] (Shared Research)
- 2024.02.09
- Notice of Recognition of Impairment Loss, and Differences between Consolidated Earnings Forecasts and Actual Results for FY2023
- 2024.02.08
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2023 [Japanese GAAP] (Consolidated)
- 2024.02.07
- Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (3rd Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
- 2024.01.23
- Preliminary Results of a Phase 2a Clinical Trial of Intravenous Brincidofovir (IV BCV) in Immunocompromised Patients with Adenovirus Infection Selected for Pediatric Best Abstracts at the 2024 Tandem Meetings of ASTCT and CIBMTR
- 2024.01.22
- Notice Regarding Adjustment of Exercise Price
- 2024.01.22
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (3rd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (3rd Allotment)
- 2024.01.19
- SymBio Granted Patent in Japan for Use of Intravenous Brincidofovir for Treatment of Adenovirus Infection and Infectious Disease
- 2024.01.16
- 株主様向け決算説明会への抽選によるご招待(Japanese only)
- 2024.01.10
- 株主通信「SymBio VISION vol.24」(Japanese only)
- 2023.12.20
- Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (2nd Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
- 2023.12.11
- SymBio Presents New Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
- 2023.12.04
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (2nd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (2nd Allotment)
- 2023.12.04
- Notice Regarding Adjustment of Exercise Price
- 2023.11.17
- Notice of Relocation of Head Office
- 2023.11.14
- Analyst Report[Flash report] (Shared Research)
- 2023.11.14
- 四半期報告書-第19期第3四半期(2023/07/01-2023/09/30) (Japanese only)
- 2023.11.14
- Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.11.14
- Revision to Earnings Forecast and Reversal of deferred tax assets for FY 2023
- 2023.11.10
- Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (1st Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
- 2023.11.06
- SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
- 2023.10.25
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (1st Allotment) through Third-Party Allotment based on the Agreement to Sept up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (1st Allotment)
- 2023.10.25
- Notice Regarding Adjustment of Exercise Price
- 2023.10.16
- Onconova Therapeutics announces Encouraging Rigosertib Data in RDEB-associated SCC Presented at EADV as Late Breaker
- 2023.10.12
- The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
- 2023.10.06
- Notice of Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Issue New Shares through Third-Party Allotment
- 2023.08.29
- Notice of Change of Global Chief Medical Officer and Appointment of Senior Vice President of SymBio Pharma USA, Inc.
- 2023.08.14
- Revision to Development Plan for IV Brincidofovir for BK virus
- 2023.08.03
- Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.08.03
- Revision to Earnings Forecast for FY 2023
- 2023.07.20
- Notice of Personnel Changes at SymBio Pharma USA, Inc.
- 2023.07.14
- Analyst Report[Full report] (Shared Research)
- 2023.06.12
- Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
- 2023.06.07
- Onconova Therapeutics Announces Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
- 2023.05.29
- IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
- 2023.05.10
- Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
- 2023.04.27
- Analyst Report[Flash report] (Shared Research)
- 2023.04.27
- Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.04.24
- SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
- 2023.04.14
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
- 2023.04.14
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
- 2023.03.24
- Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
- 2023.03.23
- Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2023.03.23
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2023.03.23
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2023.03.22
- Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
- 2023.03.01
- Information on Shareholders' Meeting: Updated the Page
- 2023.02.22
- Notification of Amendment to the Articles of Incorporation
- 2023.02.09
- Analyst Report[Flash report] (Shared Research)
- 2023.02.09
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
- 2023.02.09
- Notice concerning non-operating expenses
- 2023.01.23
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2023.01.16
- Analyst Report[Follow-up Report] (Fair Research)
- 2022.12.26
- SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
- 2022.12.19
- SymBio enters into Sponsored Research Agreement for non-clinical study to verify the effectiveness of brincidofovir in a virus-infected brain tissue model
- 2022.12.16
- SymBio files lawsuit for infringement of TREAKISYM patents
- 2022.12.14
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
- 2022.12.13
- Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
- 2022.12.12
- Analyst Report[Full report] (Shared Research)
- 2022.11.24
- SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
- 2022.11.08
- Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.11.08
- Revision to Earnings Forecast for FY 2022
- 2022.09.27
- Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
- 2022.08.31
- Notice of Appointment of Corporate Officer
- 2022.08.22
- SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
- 2022.08.09
- The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
- 2022.08.05
- Analyst Report[Update report] (Shared Research)
- 2022.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.08.04
- Revision to Earnings Forecast for FY 2022
- 2022.07.11
- SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
- 2022.06.16
- Notice of Resignation of Director
- 2022.06.14
- SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
- 2022.06.13
- SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
- 2022.06.08
- Analyst Report[Basic Report] (Fair Research)
- 2022.06.03
- Analyst Report[Full report] (Shared Research)
- 2022.06.01
- Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.24
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2022.05.18
- Chimerix announces sale of brincidofovir to Emergent BioSolutions
- 2022.05.16
- Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.11
- Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
- 2022.04.01
- Joint research agreement with the National Cancer Center on rare cancers
- 2022.03.31
- Notice of Renewal of Syndicated Loan Agreement
- 2022.03.30
- Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
- 2022.03.29
- Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2022.03.25
- Analyst Report[Full report] (Shared Research)
- 2022.03.09
- Information on Shareholders' Meeting: Updated the Page
- 2022.03.08
- SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
- 2022.03.07
- SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
- 2022.02.28
- SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
- 2022.02.25
- Response to marketing approvals of generic products
- 2022.02.24
- Notification of Amendments to the Articles of Incorporation
- 2022.02.24
- Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
- 2022.02.24
- SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
- 2022.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2022.02.10
- Notice concerning non-operating expenses
- 2022.02.10
- Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
- 2022.01.31
- Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
- 2022.01.18
- SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
- 2022.01.06
- Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
- 2021.12.24
- Notice of Appointment of Executive Vice President, Corporate Officer and COO
- 2021.12.20
- Notice of Appointment of Corporate Officer
- 2021.12.06
- Analyst Report[Follow-up Report] (Fair Research)
- 2021.12.03
- Analyst Report[Full report] (Shared Research)
- 2021.11.24
- SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
- 2021.11.11
- Analyst Report[Update report] (Shared Research)
- 2021.11.11
- Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.11.11
- Notice Concerning Non-operating Expenses
- 2021.11.11
- SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
- 2021.11.11
- SymBio announces selection of "Growth Market" as new market segment
- 2021.11.11
- Message from President of SymBio Pharma USA
- 2021.10.12
- SymBio announces commencement of operations of SymBio Pharma USA, Inc.
- 2021.09.29
- SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
- 2021.09.27
- Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
- 2021.09.21
- Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
- 2021.09.09
- Analyst Report[Research Coverage Report] (Shared Research)
- 2021.09.08
- SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
- 2021.09.01
- SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
- 2021.08.17
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
- 2021.08.04
- Analyst Report[Update report] (Shared Research)
- 2021.08.04
- Notice Concerning Non-operating Expenses
- 2021.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.08.02
- Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
- 2021.07.15
- Notice of Appointment of Corporate Officer
- 2021.07.15
- Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
- 2021.06.29
- Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
- 2021.06.23
- Notice of Changes of Director
- 2021.06.18
- Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
- 2021.06.16
- Analyst Report[Full report] (Shared Research)
- 2021.06.07
- Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
- 2021.06.01
- Analyst Report[Basic Report] (Fair Research)
- 2021.05.25
- New Patent Issued in Japan for Antiviral Agent Brincidofovir
- 2021.05.21
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2021.05.19
- Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.05.13
- Analyst Report[Update report] (Shared Research)
- 2021.05.13
- Notice of Appointment of Corporate Officer
- 2021.05.13
- Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.05.10
- SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration
- 2021.04.28
- SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.04.28
- SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.04.26
- U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
- 2021.04.26
- Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
- 2021.04.23
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2021.04.23
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2021.03.29
- SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2021.03.25
- Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
- 2021.03.25
- SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.25
- SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.24
- Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
- 2021.03.24
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2021.03.24
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2021.03.23
- SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.23
- SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.11
- SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
- 2021.03.03
- Information on Shareholders' Meeting: Updated the Page
- 2021.02.26
- Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
- 2021.02.25
- Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
- 2021.02.22
- Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- 2021.02.04
- Analyst Report[Update report] (Shared Research)
- 2021.02.04
- 3 Year Mid-Range Plan: FY 2021 to FY 2023
- 2021.02.04
- Notice Concerning Non-Operating Income
- 2021.02.04
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
- 2021.01.28
- Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
- 2021.01.12
- Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2020.12.23
- Notice of Appointment of Corporate Officer
- 2020.12.22
- Notice of Conclusion of Syndicated Loan Agreement
- 2020.12.22
- Analyst Report[Full report] (Shared Research)
- 2020.12.18
- Completion, Monthly Exercise Status and Large Volume Exercise of the 51th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.12.10
- Commencement of in-house sales of the anti-cancer agent Treakisym
- 2020.12.08
- Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
- 2020.12.03
- Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.12.01
- Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.11.26
- Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.11.24
- National Health Insurance (NHI) Price Listing and Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2020.11.11
- Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.11.10
- Analyst Report[Update report] (Shared Research)
- 2020.11.10
- Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
- 2020.11.10
- Notice Concerning Non-operating Expenses
- 2020.11.06
- Chimerix Completed Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox
- 2020.11.04
- Analyst Report[Follow-up Report] (Fair Research)
- 2020.11.02
- Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.10.13
- Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights
- 2020.09.23
- SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2020.09.17
- Analyst Report[Update report] (Shared Research)
- 2020.09.17
- Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022)
- 2020.09.10
- Analyst Report[Commercial outlook] (EDISON)
- 2020.09.09
- Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation
- 2020.09.07
- Preparation for Sales & Marketing by SymBio's Own Sales Organization
- 2020.09.01
- Final Arbitration Award in Dispute against The Medicines Company
- 2020.08.25
- Analyst Report[Full report] (Shared Research)
- 2020.08.25
- Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial for Higher-Risk Myelodysplastic Syndromes (HR-MDS)
- 2020.08.05
- Analyst Report[Update report] (Shared Research)
- 2020.08.05
- Arbitration Award in Dispute against The Medicines Company
- 2020.08.05
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
- 2020.08.05
- Notice Concerning Non-operating Expenses
- 2020.08.05
- SymBio Announces Global Development Plan of Anti-viral Drug Brincidofovir IV For Adenovirus Infectious DiseaseAfter Hematopoietic Stem Cell Transplantation
- 2020.07.30
- Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
- 2020.07.28
- Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
- 2020.07.13
- SymBio submits Partial Change Application for use of TREAKISYM in combination with polatuzumab vedotin and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2020.07.09
- Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
- 2020.06.23
- Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
- 2020.06.16
- Analyst Report[Full report] (Shared Research)
- 2020.06.01
- Completion, Monthly Exercise Status and Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.06.01
- Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.26
- Analyst Report[Clinical update] (EDISON)
- 2020.05.19
- Analyst Report[Earnings and regulatory update] (EDISON)
- 2020.05.15
- The 25th Congress of the European Hematology Association (25th EHA Annual Congress) Accepts Abstract for Phase III Clinical Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma for Publication
- 2020.05.12
- Analyst Report[Update report] (Shared Research)
- 2020.05.11
- SymBio submits Partial Change Application for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2020.05.11
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.08
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.07
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.01
- Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.30
- Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
- 2020.04.30
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
- 2020.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
- 2020.04.22
- Notice of Change (Retirement) of Director
- 2020.04.21
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.20
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2020.04.14
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.07
- Analyst Report[Basic Report] (Fair Research)
- 2020.04.01
- Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.03.27
- Notice of Shareholder Voting Results for the 15th Ordinary General Meeting of Shareholders
- 2020.03.26
- Analyst Report[Full report] (Shared Research)
- 2020.03.26
- Notice of Members of the Board of Director, Substitute Member of the Audit & Supervisory Board and Corporate Officers Appointment
- 2020.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2020.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2020.03.25
- Completion of Patient Enrollment in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
- 2020.03.25
- Onconova Announces Completion of Enrollment in Phase 3 INSPIRE Trial of IV Rigosertib
- 2020.03.16
- Completion of Payment for Subscription for the 50th and 51st Stock Acquisition Rights (with Exercise Price Revision Clauses)
- 2020.03.06
- Information on Shareholders' Meeting: Updated the Page
- 2020.02.27
- Analyst Report[Update report] (Shared Research)
- 2020.02.27
- Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)
- 2020.02.27
- Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
- 2020.02.12
- Completion, Monthly Exercise Status and Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.02.06
- Analyst Report[Update report] (Shared Research)
- 2020.02.06
- 3 Year Mid-Range Plan: FY 2020 to FY 2022
- 2020.02.06
- Notice Concerning Non-operating Expenses
- 2020.02.06
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2019[Japanese GAAP] (Non-consolidated)
- 2020.02.03
- Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.01.15
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.01.06
- Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.20
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2019.12.19
- Notice of Appointment of Corporate Officer
- 2019.12.19
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.17
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.10
- Onconova Announces Data from the INSPIRE Trial and Updated Oral Rigosertib Data at the American Society of Hematology (ASH) 2019 Annual Meeting
- 2019.12.09
- Onconova Announces Collaboration with Inceptua for Pre-approval Access to Anti-cancer Drug Rigosertib
- 2019.12.02
- Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.02
- Analyst Report[Full report] (Shared Research)
- 2019.11.27
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.11.25
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.11.12
- Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement
- 2019.11.08
- Analyst Report[Update report] (Shared Research)
- 2019.11.08
- Summary of Financial Statements for the first nine months of fiscal year ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
- 2019.11.08
- Notice Concerning Non-operating Expenses
- 2019.11.08
- Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2019 ASH Annual Meeting & Exposition
- 2019.11.07
- Analyst Report[Follow-up Report] (Fair Research)
- 2019.11.05
- SymBio Announces Achievement of Primary Endpoint (Overall Response Rate) in Phase 3 Clinical Trial of TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
- 2019.10.25
- Onconova Provides Update on the Global Phase 3 INSPIRE Trial of Rigosertib in Myelodysplastic Syndromes and on Future Clinical Trial Plans
- 2019.10.18
- Notice Regarding Inappropriate Conduct of Clinical Trial Monitor
- 2019.10.01
- SymBio Announces Exclusive Global License Agreement with Chimerix for Antiviral Drug, Brincidofovir
- 2019.09.26
- SymBio Submits New Drug Application for TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2019.09.25
- Analyst Report[Full report] (Shared Research)
- 2019.09.18
- Progress (LPLV) of Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
- 2019.08.07
- Analyst Report[Update report] (Shared Research)
- 2019.08.07
- Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022)
- 2019.08.07
- Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
- 2019.08.07
- Notice Concerning Non-operating Expenses
- 2019.07.19
- Notice Regarding Sale of Fractional Shares Due to Reverse Stock Split
- 2019.07.01
- Analyst Report[Full report] (Shared Research)
- 2019.06.17
- Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.06.13
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.06.12
- Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer
- 2019.06.11
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.06.03
- Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.05.28
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.05.22
- Launch of "Regenerative Medicine" Products that can be used with the anti-cancer drug TREAKISYM as a pretreatment agent
- 2019.05.14
- Analyst Report[Update report] (Shared Research)
- 2019.05.14
- Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
- 2019.05.14
- Notice Concerning Non-operating Expenses
- 2019.05.07
- Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2019.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2019.04.18
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.17
- Analyst Report[Corporate outlook] (EDISON)
- 2019.04.16
- Analyst Report[Basic Report] (Fair Research)
- 2019.04.12
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.10
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.10
- First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
- 2019.04.08
- Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
- 2019.04.03
- Analyst Report[Full report] (Shared Research)
- 2019.04.01
- Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.01
- Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib
- 2019.03.29
- Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders
- 2019.03.28
- Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
- 2019.03.28
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2019.03.28
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2019.03.28
- Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
- 2019.03.26
- TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy
- 2019.03.14
- Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.03.11
- Information on Shareholders' Meeting: Updated the Page
- 2019.03.05
- (Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
- 2019.02.28
- Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation
- 2019.02.28
- Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
- 2019.02.07
- SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years)
- 2019.02.07
- Notice Concerning Non-operating Expenses
- 2019.02.07
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated)
- 2018.12.20
- Shipments of the 25mg Presentation of Anti-cancer Drug TREAKISYM Intravenous Infusion Paused and Shipment of Substitute
- 2018.12.17
- Completion of Exercise of the 39th Stock Acquisition Rights Issued by way of Third Party Allotment
- 2018.12.12
- Analyst Report[Strategy update](EDISON)
- 2018.12.07
- Analyst Report[Full report] (Shared Research)
- 2018.12.04
- Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting
- 2018.11.30
- Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation)
- 2018.11.09
- Analyst Report[Update report]: Shared Research updates the report
- 2018.11.09
- Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
- 2018.11.08
- Analyst Report[Follow-up Report] (Fair Research)
- 2018.11.06
- Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2018 ASH Annual Meeting & Exposition
- 2018.10.17
- Onconova Announces Issuance of a New U.S. Patent for Rigosertib
- 2018.10.16
- SymBio Begins Preparation for Own Sales Organization for the Anti-Cancer Agent TREAKISYM
- 2018.10.01
- Completion and Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.10.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.09.27
- SymBio files Partial Change Application for use of TREAKISYM as a Pretreatment to Regenerative Medical Products
- 2018.09.25
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.09.05
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.09.03
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.08.30
- Analyst Report[Full report] (Shared Research)
- 2018.08.29
- Launch of New Anti-CD20 Antibodies that can be used in combination with the anti-cancer agent TREAKISYM
- 2018.08.29
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.08.21
- Analyst Report[Basic Report] (Fair Research)
- 2018.08.07
- Analyst Report[Update report]: Shared Research updates the report
- 2018.08.07
- Notice Concerning Non-operating Expenses
- 2018.08.07
- Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
- 2018.08.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.07.30
- Revised Medical Practice Guidelines 2018 for Healthcare Professionals
- 2018.07.25
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.07.09
- Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S.
- 2018.07.04
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.07.02
- TREAKISYM Receives Approval for Combined Use with Anti-CD20 Antibodies
- 2018.07.02
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.06.18
- Eagle Announces U.S. Court Decision Granting Orphan Drug Exclusivity for Bendamustine Hydrochloride Injection in the U.S.
- 2018.06.06
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.06.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.05.28
- Analyst Report[Full report]: Shared Research updates the report
- 2018.05.28
- First Patient Enrolled in Phase 1 Clinical Trial for Oral TREAKISYM for Progressive Solid Tumors
- 2018.05.18
- TREAKISYM Sales Forecast for FY2018
- 2018.05.10
- Analyst Report[Update report]: Shared Research updates the report
- 2018.05.10
- Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
- 2018.05.10
- Notice Concerning Non-operating Expenses
- 2018.05.10
- Initiation of Collaborative Research with Keio University on TREAKISYM for Systemic Lupus Erythematosus
- 2018.05.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.04.26
- (Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2018.04.26
- (Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2018.04.26
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2018.04.26
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2018.04.25
- Completion of Payment for Subscription for the 45th through 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
- 2018.04.18
- TREAKISYM Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma
- 2018.04.09
- Analyst Report[Update report]: Shared Research updates the report
- 2018.04.09
- Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement
- 2018.03.30
- Notice of Shareholder Voting Results for the 13th Ordinary General Meeting of Shareholders
- 2018.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2018.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2018.03.29
- Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
- 2018.03.27
- Analyst Report[Full report]: Shared Research updates the report
- 2018.03.13
- Information on Shareholders' Meeting: Updated the Page
- 2018.03.06
- Notice concerning Nominations for the Board of Directors/the Audit & Supervisory Board/and Substitute Member for the Audit & Supervisory Board
- 2018.02.19
- Analyst Report[Basic Report]: Fair Research updates the report
- 2018.02.09
- Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2018.02.07
- Analyst Report[Update report]: Shared Research updates the report
- 2018.02.07
- SymBio's Mid-Range Plan: FY2018 to FY2021
- 2018.02.07
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated)
- 2018.02.07
- Notice Concerning Non-Operating Income
- 2018.01.22
- Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
- 2018.01.18
- Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis
- 2017.12.08
- Analyst Report[Full report]: Shared Research updates the report
- 2017.11.30
- Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company
- 2017.11.13
- Initiation of an Arbitration against The Medicines Company
- 2017.11.10
- Analyst Report[Update report]: Shared Research updates the report
- 2017.11.10
- Notice Concerning Non-operating Income
- 2017.11.10
- Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated)
- 2017.11.02
- Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting
- 2017.10.23
- Analyst Report: Edison updates the report
- 2017.10.16
- Analyst Report[Full report]: Shared Research updates the report
- 2017.10.10
- Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
- 2017.09.21
- Analyst Report[Update report]: Shared Research updates the report
- 2017.09.21
- Notice of Revision to the Earnings Forecast for FY2017
- 2017.09.21
- Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
- 2017.09.20
- Analyst Report[Full report]: Shared Research updates the report
- 2017.08.31
- Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
- 2017.08.30
- Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
- 2017.08.25
- Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
- 2017.08.09
- Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
- 2017.08.09
- Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2017.08.03
- Analyst Report[Update report]: Shared Research updates the report
- 2017.08.03
- Notice Concerning Non-operating Income
- 2017.08.03
- Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
- 2017.07.26
- Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies"
- 2017.07.05
- Dr. Koichi Takahashi, Assistant Professor, The University of Texas MD Anderson Cancer Center, has been appointed as a member of the SAB.
- 2017.06.30
- Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
- 2017.06.05
- SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2017.06.05
- Analyst Report[Full report]: Shared Research updates the report
- 2017.05.11
- Analyst Report[Update report]: Shared Research updates the report
- 2017.05.11
- Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
- 2017.05.11
- Notice Concerning Non-operating Expenses
- 2017.05.11
- Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2017.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2017.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2017.03.30
- Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders
- 2017.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
- 2017.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
- 2017.03.29
- Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers
- 2017.03.28
- Analyst Report[Full report]: Shared Research updates the report
- 2017.03.06
- Information on Shareholders' Meeting: Updated the Page
- 2017.02.24
- Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates
- 2017.02.24
- Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment
- 2017.02.09
- Analyst Report[Update report]: Shared Research updates the report
- 2017.02.09
- SymBio's Mid-Range Plan: FY2017 to FY2019
- 2017.02.09
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated)
- 2017.02.09
- Notice Concerning Non-Operating Income
- 2017.02.01
- Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
- 2016.12.19
- Analyst Report: Shared Research updates the report
- 2016.12.19
- Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- 2016.12.06
- Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting
- 2016.11.22
- Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
- 2016.11.14
- Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting
- 2016.11.11
- Analyst Report: Shared Research updates the report
- 2016.11.11
- Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
- 2016.11.11
- Notice concerning Non-operating Expenses
- 2016.10.20
- Information on The Extraordinary Shareholders' Meeting: Updated the Page
- 2016.10.03
- Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders
- 2016.09.28
- Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg
- 2016.09.27
- Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes
- 2016.09.15
- Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
- 2016.09.15
- Notice concerning Partial Amendment to the Articles of Incorporation
- 2016.09.12
- Analyst Report: Shared Research updates the report
- 2016.08.26
- Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia
- 2016.08.04
- Analyst Report: Shared Research updates the report
- 2016.08.04
- Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
- 2016.08.04
- Notice Concerning Non-operating Expenses
- 2016.07.19
- Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)
- 2016.06.16
- Corporate governance policies
- 2016.06.14
- Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
- 2016.06.13
- Analyst Report: Shared Research updates the report
- 2016.06.13
- Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
- 2016.06.08
- Notice concerning the Change of Major Shareholder
- 2016.06.07
- Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting
- 2016.06.02
- Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting
- 2016.05.30
- Notice concerning the Change of Major Shareholder
- 2016.05.24
- Notice concerning the Change of Major Shareholder
- 2016.05.20
- Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor
- 2016.05.19
- Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders
- 2016.05.11
- SymBio Announces Incorporation of its U.S. Subsidiary
- 2016.05.10
- Analyst Report: Shared Research updates the report
- 2016.05.10
- Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
- 2016.05.10
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
- 2016.05.10
- Notice Concerning Non-operating Expenses
- 2016.04.22
- Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
- 2016.04.14
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2016.04.14
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2016.04.06
- Analyst Report: Shared Research updates the report
- 2016.04.06
- Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
- 2016.03.31
- (Correction) Notice concerning partial correction to the "Notice of Appointment of Directors"
- 2016.03.31
- Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders
- 2016.03.30
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
- 2016.03.30
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
- 2016.03.30
- Notice of Appointment of Directors
- 2016.03.23
- Analyst Report: Edison updates the report
- 2016.03.21
- Analyst Report: Edison updates the report
- 2016.03.17
- Analyst Report: Shared Research updates the report
- 2016.03.11
- Information on Shareholders' Meeting: Updated the Page
- 2016.03.10
- Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates
- 2016.03.10
- Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS
- 2016.02.10
- Analyst Report: Shared Research updates the report
- 2016.02.10
- SymBio's Long Range Plan: FY2016 to FY2018
- 2016.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
- 2016.02.10
- Notice Concerning Non-operating Expenses
- 2016.02.08
- SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
- 2016.02.04
- Assessment Status of Bendamustine in Europe
- 2015.12.28
- SymBio starts Global Phase 3 Trial for IV Rigosertib
- 2015.12.24
- SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL
- 2015.12.24
- SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication)
- 2015.12.24
- SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength)
- 2015.12.08
- Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
- 2015.12.08
- Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib
- 2015.12.07
- Analyst Report: Shared Research updates the report
- 2015.12.07
- Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
- 2015.12.01
- Analyst Report: Edison updates the report
- 2015.11.30
- Analyst Report: Edison updates the report
- 2015.11.24
- SymBio Partner Announces European Approval of IONSYS®
- 2015.11.06
- Analyst Report: Shared Research updates the report
- 2015.11.06
- Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
- 2015.11.06
- Notice Concerning Non-operating Expenses
- 2015.10.30
- Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS
- 2015.10.19
- Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia
- 2015.10.19
- SymBio to Participate in Global Phase 3 Trial for IV Rigosertib
- 2015.10.06
- The article regarding "Establishment of Strategic Partnership for IONSYS® between The Medicines Company and SymBio" was posted on WSJ
- 2015.10.05
- SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan.
- 2015.09.03
- Analyst Report: Shared Research updates the report
- 2015.08.28
- Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
- 2015.08.17
- Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
- 2015.08.17
- Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
- 2015.08.05
- Analyst Report: Shared Research updates the report
- 2015.08.05
- Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
- 2015.08.05
- Notice Concerning Non-operating income
- 2015.06.26
- Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS
- 2015.05.07
- Analyst Report: Shared Research updates the report
- 2015.05.07
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
- 2015.05.07
- Notice Concerning Non-operating Expense
- 2015.04.10
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2015.04.10
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2015.03.27
- Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders
- 2015.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
- 2015.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
- 2015.03.26
- Notice of Director and Auditor Appointments
- 2015.03.23
- Analyst Report: Shared Research updates the report
- 2015.03.18
- Notice Concerning Change in Status of Major shareholder
- 2015.03.06
- Information on Shareholders' Meeting: Updated the Page
- 2015.03.05
- Notice of Nomination of Director Candidates and Auditor Candidates
- 2015.02.12
- Analyst Report: Shared Research updates the report
- 2015.02.10
- SymBio's Long Range Plan: FY2015 to FY2017
- 2015.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2014[Japanese GAAP] (Non-consolidated)
- 2015.02.10
- Notice Concerning Non-Operating Income
- 2015.02.03
- Onconova Announces its Clinical Development Plan for Rigosertib in MDS
- 2015.01.26
- Establishment of Sponsored ADR (American Depositary Receipt) Program
- 2015.01.13
- SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program
- 2015.01.13
- Completion of Patient Enrollment of rigosertib (SyB L-1101, IV) Phase I Trial in Patient with refractory or relapsed myelodysplastic syndrome (MDS)
- 2014.12.24
- Notice of Revision of the Long Range Plan: FY2014 to FY2016
- 2014.12.24
- SymBio's Long Range Plan: FY2014 to FY2016 (Revised Version)
- 2014.12.01
- Analyst Report: Shared Research initiates coverage on SymBio
- 2014.12.01
- Completion of Payment for Subscription of the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
- 2014.11.14
- Notice of the Subscription for the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
- 2014.11.13
- Notice of Revision of the Financial Forecast for FY2014
- 2014.11.07
- Notice Concerning Non-Operation Income
- 2014.11.07
- Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
- 2014.11.06
- Completion of Patient Enrollment of TREAKISYM® Phase II Trial in Patient with Chronic Lymphocytic Leukemia (CLL)
- 2014.10.13
- Analyst Report: Edison initiates coverage on SymBio
- 2014.09.19
- Notice Concerning Change in Status of Major shareholder
- 2014.09.18
- Notice Concerning Relocation of Head Office
- 2014.08.14
- Onconova's Announcement in the Development of Rigosertib for patients with MDS in Second Quarter 2014
- 2014.08.06
- Notice Concerning Non-Operation Expense
- 2014.08.06
- Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
- 2014.06.18
- SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine Hydrochloride (SyB L-0501)
- 2014.05.08
- Notice Concerning Non-Operation Expense
- 2014.05.08
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
- 2014.04.30
- Notice Concerning Adjustment to Exercise Price of Stock Option
- 2014.04.30
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2014.04.30
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2014.04.15
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
- 2014.04.15
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
- 2014.03.28
- Notice of Shareholder Voting Results for the 9th Ordinary General Meeting of Shareholders
- 2014.03.27
- Notice Concerning the Appointment of Directors
- 2014.03.27
- Announcement Personnel Changes
- 2014.03.06
- Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors
- 2014.03.06
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
- 2014.02.20
- Onconova Announces Results from Phase 3 ONTIME Study of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)
- 2014.02.20
- SymBio's Long Range Plan: FY2014 to FY2016
- 2014.02.12
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2013[Japanese GAAP](Non-consolidated)
- 2013.12.18
- Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study
- 2013.12.10
- Onconova Presents Phase 2 Data for Oral Rigosertib at 2013 American Society of Hematology Annual Meeting
- 2013.11.27
- SymBio Announces Pricing of Secondary Offering and Overallotment
- 2013.11.19
- SymBio Announces Issuance of New Shares and Secondary Offering of Shares
- 2013.11.14
- Onconova Therapeutics, Inc. Reports Third Quarter 2013 Financial and Operational Results
- 2013.11.08
- Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-Consolidated)
- 2013.11.01
- TREAKISYM® PhaseⅡ Trial in Multiple Myeloma
- 2013.10.18
- Dr. George Morstyn (outside Board Director) has been elected a fellow of ATSE (The Australian Academy of Technological Sciences and Engineering).
- 2013.08.07
- Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-Consolidated)
- 2013.07.26
- SymBio Announces Revised Financial Forecast
- 2013.06.03
- Onconova Presents Phase II Data for Oral Rigosertib at 2013 American Society of Clinical Oncology Annual Meeting - Oral Rigosertib (ON 01910.Na) in Transfusion-Dependent Lower Risk MDS
- 2013.05.14
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-consolidated)
- 2013.05.10
- Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes
- 2013.05.08
- SymBio Initiates Japanese Phase II Trial for TREAKISYM® (Bendamustine) in CLL
- 2013.05.07
- JCO (Journal of Clinical Oncology)- Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- 2013.03.28
- Dr. Milton H. Grannatt Joins SymBio as Outside Director
- 2013.03.26
- SymBio Initiates Japanese Phase I Trial of Oral rigosertib (SyB C-1101) in Frontline MDS
- 2013.03.15
- SYMBIO AND EISAI ANNOUNCE REMOVAL OF TREAKISYM® INJECTION 100 MG ALL CASES SURVEILLANCE CONDITION FOR JAPAN MARKETING APPROVAL
- 2013.03.06
- Completion of Patient Enrollment of TREAKISYM® (SyB L-0501) Phase II Trial in Frontline Low-grade Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma
- 2013.02.20
- The Lancet(Online First) - Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- 2013.02.14
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2012 [Japanese GAAP] (Non-consolidated)
- 2013.01.28
- SymBio Completes Phase 2 Trial of Antiemetic Transdermal Patch (SyB D-0701) in RINV
- 2013.01.07
- SymBio Receives Clinical Trial Notification Acceptance for Phase 2 TREAKISYM® (Bendamustine) Trial in CLL
- 2012.12.27
- Notice of Issuance of 1st Unsecured Convertible Bond with Stock Acquisition Rights and 29th Warrant by Third-Party Allotment
- 2012.12.27
- Clinical Trial Notification Accepted by Japanese Regulatory Agency for SymBio's Phase I Oral Rigosertib (SyB C-1101) Trial in Frontline MDS
- 2012.11.09
- SymBio Announces Revised Financial Forecast
- 2012.11.09
- Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2012 [Japan GAAP] (Non-consolidated)
- 2012.10.24
- SymBio Announces Completion of Patient Enrollment for Phase II Clinical Trial of SyB D-0701 in RINV
- 2012.09.20
- Onconova Closes Deal with Baxter (BAX) for Rigosertib in Europe
- 2012.08.08
- Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2012 [Japan GAAP] (Non-consolidated)
- 2012.06.29
- SymBio Initiates Japanese Phase I Trial of Rigosertib (SYB L-1101) in Relapsed/Refractory MDS
- 2012.06.14
- SymBio Announces Orphan Drug Designation for TREAKISYM® (Bendamustine) in Chronic Lymphocytic Leukemia (CLL)
- 2012.06.04
- SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM® (Bendamustine) in Combination with Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- 2012.06.01
- SymBio Announces Data Presentations at 48th Annual American Society of Clinical Onoclogy Meeting
- 2012.05.30
- SymBio Announces Development Status of TREAKISYM® in Refractory and Relapsed Aggressive Non-Hodgkin's Lymphoma
- 2012.05.15
- Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes
- 2012.05.11
- Financial Results for the First Quarter of Fiscal Year Ended December 31, 2012 [Japan GAAP] (Non-consolidated)
- 2012.04.16
- SymBio Announces Presentation at BioCentury Future Leaders in the Biotech Industry Conference
- 2012.03.29
- Clinical Trial Notificaation Accepted for SymBio's Japan Phase 1 Trial of Rigosertib(SyB L-1101) in Refractory/Relapsed MDS
- 2012.03.09
- 7th Term General Shareholders' Meeting
- 2012.02.24
- SymBio Announces Bendamustine Hydrochloride(SyB L-0501) Launch in Taiwan
- 2012.02.14
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2011 [Japan GAAP](Non-consolidated)
- 2011.12.26
- SymBio Initiates Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Multiple Myeloma
- 2011.12.13
- Onconova Presents Phase Ⅰ Data for Oral Rigosertib at the 53rd American Society of Hematology Annual Meeting
- 2011.11.14
- Clinical Trial Notification Accepted for SymBio's Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Multiple Myeloma
- 2011.11.11
- Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2011
- 2011.11.10
- SymBio Initiates Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Frontline Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- 2011.10.25
- Results of Third Party Allocation of New Shares
- 2011.10.21
- SymBio Announces Taiwan NDA Approval of Bendamustine Hydrochloride(SyB L-0501)
- 2011.10.20
- SymBio Pharmaceuticals Limited was listed on Osaka Securities Exchange JASDAQ Growth Market
- 2011.10.20
- Financial Disclosure for SymBio’s New Listing on Osaka Securities Exchange JASDAQ Growth Market
- 2011.10.19
- Homepage renewal
- 2011.10.11
- Determination of Issuance Price Per Share, Equity Offering Price and Number of Shares by Overallotment
- 2011.09.29
- Amount to Be Paid for New Shares and Tentative Terms for Book Building
- 2011.09.14
- Corporate Resolution for SymBio’s Initial Public Offering of Shares on JASDAQ
- 2011.08.26
- BioCentury article on Rigosertib deal between SymBio and Onconova
- 2011.07.11
- Onconova and SymBio Complete License Agreement for Rigosertib, a Phase Ⅲ Stage Multi-Kinase Inhibitor for Cancer
- 2011.06.03
- SymBio Announces Korea NDA Approval of Bendamustine Hydrochloride (SyB L-0501)
- 2011.05.11
- The news of Human Resources
- 2011.02.25
- SymBio Pharmaceuticals Successfully Completes JPY2.0 Billion (USD24 Million) Series E Private Placement
- 2010.12.10
- SymBio Launches TREAKISYM® in Japan
- 2010.10.27
- SymBio Announces Japan NDA Approval of TREAKISYM®(Bendamustine Hydrochloride)
- 2010.10.04
- News Flash: Pharmaceutical Affairs Subcommittee of MHLW recommended approval for SyB L-0501 (bendamustine HCI)from SymBio, on October 1st.
- 2010.09.07
- SymBio and Eisai to Launch Symbenda® (Bendamustine Hydrochloride) in Singapore for the Treatment of Low-grade Non-Hodgkin’s Lymphoma and Chronic Lymphatic Leukemia
- 2010.09.06
- News Flash: Second Committees of CDFS (Japan’s Committees on New Drugs, Pharmaceutical Affairs Section) recommended approval for SyB L-0501 (bendamustine HCI)from SymBio, on August 30.
- 2010.08.17
- The news of Human Resources
- 2010.07.05
- SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in Multiple Myeloma
- 2010.03.17
- NDA Submission for Bendamustine HCl (SyB L-0501) in Taiwan
- 2010.03.04
- SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in Aggressive Non-Hodgkin’s Lymphoma
- 2010.01.28
- SymBio Pharmaceuticals Closes Oversubscribed 2.2 billion JPY(USD24.4 million) Series D Financing with Completion of Payment for New Shares through Third Party Allotment
- 2010.01.27
- Bendamustine HCl (SyB L-0501) Approved in Singapore and Hong Kong
- 2009.12.11
- SymBio Pharmaceuticals Limited Announces Completion of Third Party Allocation of New Shares
- 2009.10.30
- NDA Submission for SyB L-0501 (bendamustine hydrochloride)
- 2009.06.22
- symbiopharma.com renewal!
- 2009.05.18
- SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore
- 2009.04.15
- SymBio Pharmaceuticals Limited Executes Third Party Allocation of New Shares to Mitsubishi UFJ Capital Limited Partnership Fund
- 2009.04.15
- SymBio Pharmaceuticals Limited Executes Third Party Allocation of New Shares to Cephalon, Inc. - Payment of 888,480 thousand JPY (USD 9 Mil) Complete
- 2009.04.02
- SymBio Pharmaceuticals Limited Concludes Sublicense Agreement Granting Cephalon, Inc. Development and Commercialization Rights for Bendamustine Hydrochloride in China
- 2009.03.09
- SyB L-0501 Phase II Trial Results in Low-Grade Non-Hodgkin’s Lymphoma Reviewed by Independent Data Monitoring Committee
- 2009.02.27
- TREANDA® (Cephalon, Inc.) is selected as a finalist as Pharmaceutical Executive Magazine’s ‘Brand of the Year’
- 2009.01.08
- SyB L-0501 Product Registration Dossiers Submitted in Singapore
- 2008.12.26
- First Patient In for SyB L-0501 Phase I Trial to Treat Patients with Aggressive Non-Hodgkin's Lymphoma (NHL).
- 2008.11.04
- Cephalon Receives FDA Approval for Bendamustine Hydrochloride to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
- 2008.08.18
- SymBio Pharmaceuticals and Eisai Sign License Agreement for SyB L-0501
- 2008.07.17
- SymBio Completes Phase I Clinical Trials of SyB D-0701 for Chemotherapy Induced Nausea and Vomiting.
- 2008.06.20
- SymBio Completes Patient Enrollment for Mantle Cell Lymphoma in SyB L-0501 Phase II Clinical Study
- 2008.05.21
- SymBio Completes Enrollment of Japanese Patients with Indolent non-Hodgkin's Lymphoma in SyB L-0501 Phase II Clinical Study
- 2008.03.26
- SymBio Pharmaceuticals Signs License Agreements with Yuhan Yang Haeng and InnoPharmax for South Korea and Taiwan Markets
- 2008.03.25
- The U.S. Food and Drug Administration (FDA) has approved New Drug Application for Bendamustine Hydrochloride
- 2008.02.25
- FDA Accepts Bendamustine Hydrochloride New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
- 2008.01.07
- Cephalon Submits New Drug Application for Bendamustine Hydrochloride for the Treatment of Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma
- 2007.12.06
- Bendamustine Hydrochloride New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
- 2007.12.05
- Commencement of Phase 2 Clinical Study of SymBio Pharmaceuticals’ First New Drug, SyB L-0501
- 2007.11.16
- Cephalon Announces Positive Results from Its Pivotal Study of Bendamustine Hydrochloride in Patients with Non-Hodgkin's Lymphoma. Company on Target to File Second New Drug Application for Bendamustine Hydrochloride by End of 2007
- 2007.10.02
- Cephalon US has submitted New Drug Application for Bendamustine Hydrochloride
- 2007.09.05
- SymBio Pharmaceuticals Limited Obtains Global Exclusive Rights for Pegylated Zinc Protoporphyrin (SyB 0702) against Gleevec-resistant Leukemia Cells
- 2007.05.17
- An interview with Mr. Fuminori Yoshida, President & CEO of SymBio, was published in the May 15th issue of the "Journal of Pharmaceutical Business" (Japanese version only)
- 2007.04.24
- SymBio Pharmaceuticals Signs Agreement with Astellas Deutschland GmbH: In-Licenses Rights to”SyB L-0501” in Key Asia-Pacific Rim Countries
- 2007.03.16
- Abeille Pharmaceuticals Licenses SyB D-0701 To SymBio Pharmaceuticals For Commercialization in Japan and Pacific RIM Countries
- 2007.03.08
- SymBio Completes Patient Enrollment in the Phase I Clinical Trial of SyB L-0501